WordNet
- cultivate by growing, often involving improvements by means of agricultural techniques; "The Bordeaux region produces great red wines"; "They produce good ham in Parma"; "We grow wheat here"; "We raise hogs here" (同)raise, farm, produce
- come to have or undergo a change of (physical features and attributes); "He grew a beard"; "The patient developed abdominal pains"; "I got funny spots all over my body"; "Well-developed breasts" (同)develop, produce, get, acquire
- become attached by or as if by the process of growth; "The tree trunks had grown together"
- become larger, greater, or bigger; expand or gain; "The problem grew too large for me"; "Her business grew fast"
- cause to grow or develop; "He grows vegetables in his backyard"
- increase in size by natural process; "Corn doesnt grow here"; "In these forests, mushrooms grow under the trees"; "her hair doesnt grow much anymore"
- (biology) the process of an individual organism growing organically; a purely biological unfolding of events involved in an organism changing gradually from a simple to a more complex level; "he proposed an indicator of osseous development in children" (同)growing, maturation, development, ontogeny, ontogenesis
- (pathology) an abnormal proliferation of tissue (as in a tumor)
- a progression from simpler to more complex forms; "the growth of culture"
- something grown or growing; "a growth of hair"
- vegetation that has grown; "a growth of trees"; "the only growth was some salt grass"
- be a contributing factor; "make things factor into a companys profitability"
- any of the numbers (or symbols) that form a product when multiplied together
- an independent variable in statistics
- anything that contributes causally to a result; "a number of factors determined the outcome"
- consider as relevant when making a decision; "You must factor in the recent developments" (同)factor in, factor out
- resolve into factors; "a quantum computer can factor the number 15" (同)factor in, factor out
- an event known to have happened or something known to have existed; "your fears have no basis in fact"; "how much of the story is fact and how much fiction is hard to tell"
- a concept whose truth can be proved; "scientific hypotheses are not facts"
- a piece of information about circumstances that exist or events that have occurred; "first you must collect all the facts of the case"
- a statement or assertion of verified information about something that is the case or has happened; "he supported his argument with an impressive array of facts"
- a cellular structure that is postulated to exist in order to mediate between a chemical agent that acts on nervous tissue and the physiological response
PrepTutorEJDIC
- 『成長する』,育つ,〈植物が〉生える,茂る / (類・量・程などにおいて)『増大する』,大きくなる / 『しだいになる』 / …‘を'成長させる,大きくする,育てる / …から生じる(起こる)
- 〈U〉(…の)『成長』,発育;『発達』,発展《+『of』+『名』》 / 〈U〉(数・量,重要性・力などの)『増加』,増大,拡張《+『of』+『名』》 / 〈U〉《修飾語[句]を伴って》栽培,生産,…産 / 〈C〉成育した物,(草,木,髪,ひげなどの)生えたもの / 〈C〉腫瘍(しゅよう)
- (…の)『要因』,(…を生み出す)要素《+『in』+『名』(do『ing』)》 / 囲数,約数 / 代理人,《おもに英》仲買人 / =factorize
- 〈C〉『事実』,実際にある(あった)事 / 〈U〉真相,真実(truth) / 《the~》(法律用語で)犯行
- =sense organ / 受信装置
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 上皮成長因子受容体変異を有する進行性非小細胞肺癌に対する初期全身療法 initial systemic therapy for advanced non small cell lung cancer with a mutation in the epidermal growth factor receptor
- 2. 未分化リンパ腫キナーゼ（ALK）融合癌遺伝子陽性非小細胞肺癌 anaplastic lymphoma kinase alk fusion oncogene positive non small cell lung cancer
- 3. 転移性乳癌の全身治療：分子標的治療 systemic treatment for metastatic breast cancer molecular targeted therapy
- 4. 上皮成長因子受容体変異またはALK融合癌遺伝子を有さない進行性非小細胞肺癌に対
する初期全身化学療法 initial systemic chemotherapy for advanced non small cell lung cancer without an epidermal growth factor receptor mutation or the alk fusion oncogene - 5. 悪性神経膠腫に対する実験的治療アプローチ experimental treatment approaches for malignant gliomas
English Journal
- In-situ detection of resveratrol inhibition effect on epidermal growth factor receptor of living MCF-7 cells by Atomic Force Microscopy.
- Zhang L1, Yang F1, Cai JY1, Yang PH2, Liang ZH3.Author information 1Department of Chemistry, Jinan University, Guangzhou 510632, PR China.2Department of Chemistry, Jinan University, Guangzhou 510632, PR China. Electronic address: typh@jnu.edu.cn.3Experiment and Technology Center, Jinan University, Guangzhou 510632, PR China. Electronic address: zhihong3615@sina.com.AbstractA new method based on Atomic Force Microscopy (AFM) was developed to real-time and in-situ detect epidermal growth factor receptor (EGFR) expression levels on living MCF-7 cells for evaluating the anticancer activity of resveratrol. Here, the inhibition effect of resveratrol on EGFR expression levels on MCF-7 cells was probed by epidermal growth factor (EGF)-functionalized tips for the first time. Changes in morphology and stiffness of single cell stimulated by resveratrol at different concentrations were detected by AFM. The consequences showed that resveratrol influenced the cellular state and reduced expression of EGFR on the cell surface, which were also interpreted by MTT assay and confocal microscopy assay. AFM, which was used to investigate potential targets for anti-tumor drug on living cells and realize a better understanding of drug action mechanism, was expected to be developed into a promising tool for screening of drugs.
- Biosensors & bioelectronics.Biosens Bioelectron.2014 Jun 15;56:271-7. doi: 10.1016/j.bios.2014.01.024. Epub 2014 Jan 24.
- A new method based on Atomic Force Microscopy (AFM) was developed to real-time and in-situ detect epidermal growth factor receptor (EGFR) expression levels on living MCF-7 cells for evaluating the anticancer activity of resveratrol. Here, the inhibition effect of resveratrol on EGFR expression level
- PMID 24514079
- Caveolin 1 is critical for abdominal aortic aneurysm formation induced by angiotensin II and inhibition of lysyl oxidase.
- Takayanagi T1, Crawford KJ, Kobayashi T1, Obama T1, Tsuji T1, Elliott KJ1, Hashimoto T2, Rizzo V, Eguchi S1.Author information 1*Cardiovascular Research Center, Department of Physiology, Temple University School of Medicine, Philadelphia, PA 19140, U.S.A.2‡Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA 94110, U.S.A.AbstractAlthough AngII (angiotensin II) and its receptor AT1R (AngII type 1 receptor) have been implicated in AAA (abdominal aortic aneurysm) formation, the proximal signalling events primarily responsible for AAA formation remain uncertain. Caveolae are cholesterol-rich membrane microdomains that serve as a signalling platform to facilitate the temporal and spatial localization of signal transduction events, including those stimulated by AngII. Cav1 (caveolin 1)-enriched caveolae in vascular smooth muscle cells mediate ADAM17 (a disintegrin and metalloproteinase 17)-dependent EGFR (epidermal growth factor receptor) transactivation, which is linked to vascular remodelling induced by AngII. In the present study, we have tested our hypothesis that Cav1 plays a critical role for the development of AAA at least in part via its specific alteration of AngII signalling within caveolae. Cav1-/- mice and the control wild-type mice were co-infused with AngII and β-aminopropionitrile to induce AAA. We found that Cav1-/- mice with the co-infusion did not develop AAA compared with control mice in spite of hypertension. We found an increased expression of ADAM17 and enhanced phosphorylation of EGFR in AAA. These events were markedly attenuated in Cav1-/- aortas with the co-infusion. Furthermore, aortas from Cav1-/- mice with the co-infusion showed less endoplasmic reticulum stress, oxidative stress and inflammatory responses compared with aortas from control mice. Cav1 silencing in cultured vascular smooth muscle cells prevented AngII-induced ADAM17 induction and activation. In conclusion, Cav1 appears to play a critical role in the formation of AAA and associated endoplasmic reticulum/oxidative stress, presumably through the regulation of caveolae compartmentalized signals induced by AngII.
- Clinical science (London, England : 1979).Clin Sci (Lond).2014 Jun 1;126(11):785-94. doi: 10.1042/CS20130660.
- Although AngII (angiotensin II) and its receptor AT1R (AngII type 1 receptor) have been implicated in AAA (abdominal aortic aneurysm) formation, the proximal signalling events primarily responsible for AAA formation remain uncertain. Caveolae are cholesterol-rich membrane microdomains that serve as
- PMID 24329494
- The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
- Jeannot V1, Busser B, Brambilla E, Wislez M, Robin B, Cadranel J, Coll JL, Hurbin A.Author information 1INSERM U823, Grenoble, France; University UJF Grenoble 1, Grenoble, France.AbstractTo select the appropriate patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), it is important to gain a better understanding of the intracellular pathways leading to EGFR-TKI resistance, which is a common problem in patients with lung cancer. We recently reported that mutant KRAS adenocarcinoma is resistant to gefitinib as a result of amphiregulin and insulin-like growth factor-1 receptor overexpression. This resistance leads to inhibition of Ku70 acetylation, thus enhancing the BAX/Ku70 interaction and preventing apoptosis. Here, we determined the intracellular pathways involved in gefitinib resistance in lung cancers and explored the impact of their inhibition. We analyzed the activation of the phosphatidyl inositol-3-kinase (PI3K)/AKT pathway and the mitogen-activated protein kinase/extracellular-signal regulated kinase (MAPK/ERK) pathway in lung tumors. The activation of AKT was associated with disease progression in tumors with wild-type EGFR from patients treated with gefitinib (phase II clinical trial IFCT0401). The administration of IGF1R-TKI or amphiregulin-directed shRNA decreased AKT signaling and restored gefitinib sensitivity in mutant KRAS cells. The combination of PI3K/AKT inhibition with gefitinib restored apoptosis via Ku70 downregulation and BAX release from Ku70. Deacetylase inhibitors, which decreased the BAX/Ku70 interaction, inhibited AKT signaling and induced gefitinib-dependent apoptosis. The PI3K/AKT pathway is thus a major pathway contributing to gefitinib resistance in lung tumors with KRAS mutation, through the regulation of the BAX/Ku70 interaction. This finding suggests that combined treatments could improve the outcomes for this subset of lung cancer patients, who have a poor prognosis.
- International journal of cancer. Journal international du cancer.Int J Cancer.2014 Jun 1;134(11):2560-71. doi: 10.1002/ijc.28594. Epub 2013 Dec 13.
- To select the appropriate patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), it is important to gain a better understanding of the intracellular pathways leading to EGFR-TKI resistance, which is a common problem in patients with lung cancer. We recen
- PMID 24374738
Japanese Journal
- ゲノム解析による個別化治療の現状と今後の方向性 肺がん (特集 次世代シークエンス(NGS)を含むゲノム解析技術の導入による新しい個別化治療の展開)
- 平井 文彦,瀬戸 貴司
- 腫瘍内科 14(4), 348-354, 2014-10
- NAID 40020243006
- Drug Resistance to EGFR Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer
- Shien Kazuhiko,Yamamoto Hiromasa,Soh Junichi,Miyoshi Shinichiro,Toyooka Shinichi
- Acta Medica Okayama 68(4), 191-200, 2014-08
- … Non-small cell lung cancer (NSCLC) harboring an activating mutation within the epidermal growth factor receptor (EGFR) was defined as a clinically distinct molecular group. … These lesions show oncogene addiction to EGFR and dramatic responses to the EGFR tyrosine kinase inhibitors (TKIs). …
- NAID 120005465582
- 4. 分子標的治療薬(<特集>肺癌治療の最近の動向)
- 須田 健一,光冨 徹哉
- 日本外科学会雑誌 115(3), 130-136, 2014-05-01
- NAID 110009818534
Related Links
- 1. Drugs. 2000;60 Suppl 1:15-23; discussion 41-2. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Raymond E, Faivre S, Armand JP. Department of Medicine, Institute Gustave-Roussy, Villejuif ...
- Epidermal Growth Factor Receptor - Antigen Background Epidermal growth factor receptor (EGFR) is a transmembrane protein receptor of 170 kD with tyrosine kinase activity.... ... Antigen Background Epidermal growth factor ...
Related Pictures
★リンクテーブル★
| リンク元 | 「EGF receptor」「上皮成長因子受容体キナーゼ」「上皮増殖因子受容体キナーゼ」 |
| 関連記事 | 「grow」「fact」「factor」「kinase」「epidermal」 |
「EGF receptor」
「上皮成長因子受容体キナーゼ」
「上皮増殖因子受容体キナーゼ」
「grow」
- v.
「fact」
- n.
「factor」
- n.
「kinase」
[★] キナーゼ カイネース リン酸化酵素 phosphoenzyme phosphotransferase
「epidermal」
- adj.
- 上皮性の、表皮性の